At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment
In Brief
A Phase 2 clinical trial evaluating Placebo, Selgantolimod, and 1 other intervention for Chronic Hepatitis B. Completed, enrolled 67 participants across 10 sites in 3 countries.
Detailed Summary
The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB) who are viremic and not currently being treated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesCanada, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionDec 2019
Study CompletionApr 2021
TodayJul 2026
First PostedAug 3, 2018
Enrollment StartAug 28, 2018
Primary CompletionDec 12, 2019
Study CompletionApr 12, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.9 years ago
Interventions
Placebodrug
Tablet(s) administered orally every 7 days for 24 doses in fasted state
Selgantolimoddrug
Tablet(s) administered orally every 7 days for 24 doses in fasted state
TAFdrug
Tablet(s) administered orally once daily with food